Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Future Health Care Equity ETF

36.35
-0.3464-0.94%
Post-market: 36.690.3464+0.95%16:10 EDT
Volume:15
Turnover:558
Market Cap:19.08M
PE:- -
High:36.35
Open:36.69
Low:36.35
Close:36.69
52wk High:38.66
52wk Low:31.32
Shares:525.00K
Float Shares:525.00K
Volume Ratio:0.08
T/O Rate:0.00%
Dividend:0.11
Dividend Rate:0.31%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Why Is UnitedHealth Stock (UNH) Down on Wednesday, 9/9/2026?

TIPRANKS
·
Yesterday

Merck Price Target Raised to $161.00/Share from $127.00 by Leerink Partners

Dow Jones
·
Yesterday

Top Midday Stories: Meta Launches Muse Personal AI Agent; Dow Said to Consider Exiting $20 Billion Chemicals JV With Saudi Aramco

MT Newswires Live
·
Sep 09

UnitedHealth Falls; Cites Pressure in Commercial Business

Reuters
·
Sep 09

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

Dow Jones
·
Sep 09

UnitedHealth Shares Down 5.2%

THOMSON REUTERS
·
Sep 09

Unitedhealth Group Inc Stock (UNH) Opened Down by 3.79% on Sep 9: Facts Behind the Movement

TradingKey
·
Sep 09

UnitedHealth, Alphabet Inc. Cl a Share Losses Lead Dow's 350-Point Drop

Dow Jones
·
Sep 09

UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating

MT Newswires Live
·
Sep 09

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

GlobeNewswire
·
Sep 09

ProQR Therapeutics doses first participant in AX-0811 clinical trial

TIPRANKS
·
Sep 09

Bayer initiates Phase II study of BAY 3670549 in patients with AFib

TIPRANKS
·
Sep 09

Press Release: Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "eocn" to Reflect Its New Dawn Platform for GI Innovation

Dow Jones
·
Sep 09

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

GlobeNewswire
·
Sep 09

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

GlobeNewswire
·
Sep 09

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

GlobeNewswire
·
Sep 09

Leerink Partners Adjusts Price Target on Merck & Co. to $161 From $127, Keeps Outperform Rating

MT Newswires Live
·
Sep 09

Merck & Co Inc : Leerink Partners Raises Target Price to $161 from $127

THOMSON REUTERS
·
Sep 09

Merck price target raised to $161 from $127 at Leerink

TIPRANKS
·
Sep 09

Evotec initiates clinical trial evaluating JST-018

TIPRANKS
·
Sep 09